Targeted synthetic DMARDs in current development, phase, status and mechanism of action
| Molecule | Molecule code | Mechanism of action | Pharmaceutical company/academy | Indications (axSpA/PsA) | Current development phase | Current development stage | Clinical trial no |
| Filgotinib | JAK1 inhibitor | Gilead Sciences/Galapagos | axSpA PsA | III III | Withdrawn Terminated | NCT04483700 NCT04115748 | |
| Ivarmacitinib | SHR-0302 | JAK1 inhibitor, STAT3 inhibitor | Jiangsu HengRui Medicine | axSpA PsA | III III | Recruiting Enrolling by invitation | NCT05324631 NCT04957550 |
| Brepocitinib | PF 06700841 | JAK1, TYK2 inhibitor | Pfizer | PsA | IIb | Completed | NCT03963401 |
| Deucravacitinib | BMS-986165 | TYK2 inhibitor | Bristol-Myers Squibb | PsA | III | Recruiting | NCT04908202 |
| VTX958 | TYK2 inhibitor | Ventyx Biosciences | PsA | II | Recruiting | NCT05715125 | |
| NDI-034858 | TYK2 inhibitor | Nimbus Lakshmi. | PsA | II | Recruiting | NCT05153148 | |
| CC-99677 | MAP-kinase-activated kinase 2 inhibitor | Celgene | axSpA | II | Active, not recruiting | NCT04947579 | |
| Zunsemetinib | ATI-450 | MAP-kinase-activated kinase 2 inhibitor | Aclaris Therapeutics | PsA | II | Recruiting | NCT05511519 |
| Mufemilast | Hemay005 | PDE4 inhibitor | Tianjin Hemay Pharmaceutical | axSpA | II | Not yet recruiting | NCT05407246 |
axSpA, axial spondyloarthritis; DMARDs, disease-modifying antirheumatic drugs; JAK, Janus kinase; PDE4, phosphodiesterase 4; PsA, psoriatic arthritis.